Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Average: 2018-2025

Historic Equity Average for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Equity Average rose 34.86% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 34.86%. This contributed to the annual value of $932.0 million for FY2024, which is 117.89% up from last year.
  • Crinetics Pharmaceuticals' Equity Average amounted to $1.1 billion in Q3 2025, which was down 7.50% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Equity Average ranged from a high of $1.3 billion in Q1 2025 and a low of $159.2 million during Q1 2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Equity Average averaged around $782.2 million, with its median value being $831.9 million (2024).
  • In the last 5 years, Crinetics Pharmaceuticals' Equity Average dropped by 22.46% in 2023 and then skyrocketed by 219.15% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Equity Average (Quarterly) stood at $262.8 million in 2021, then climbed by 27.05% to $333.9 million in 2022, then skyrocketed by 62.78% to $543.4 million in 2023, then soared by 98.53% to $1.1 billion in 2024, then surged by 34.86% to $1.1 billion in 2025.
  • Its Equity Average was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.